Menu

News

Studies Reveal Potential New Targeted Therapies for Common, Hard-to-Treat Cancers

ASCO Annual Meeting Features Key Advances in Ovarian, Lung and Thyroid Cancers and Leukemia May 31, 2014 – CHICAGO – Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). […]

Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study

The U.S. Food and Drug Administration (FDA) has granted first Breakthrough Therapy Designation in bladder cancer for MPDL3280A Basel, 31 May 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a Phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) shrank tumours (overall response rate) in 43 percent (13/30) […]

Studies Reveal New Strategies to Improve Quality of Life for Patients, Survivors and Caregivers

New Research Shows Value of “Less Is More” Treatment Strategies and Earlier Palliative Care, Supports New Fertility Preservation Technique for Women With Breast Cancer May 30, 2014 – CHICAGO – Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects […]

LifeMap introduces specialized cancer coverage

Plan Eases Financial Burden for Members in Crisis PORTLAND, Ore. MAY 28, 2014 – LifeMap Assurance Company has launched a new cancer-specific critical illness plan. LifeMap Cancer Care helps members manage a life-altering cancer diagnosis that could affect their income and their families’ way of life. As the newest addition to the LifeMap critical illness […]

FDA Approves Roche’s HPV Test for First-Line Primary Screening for Cervical Cancer

Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older Basel, 25 April 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) approved the cobas HPV (Human Papillomavirus) […]

FDA Advisory committee unanimously recommends Roche’s HPV Test as primary screening tool for detection of women at high risk for cervical cancer

Basel, 13 March 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV (Human Papillomavirus) Test as a first line, primary screening tool in women 25 years and older […]

«‹ 5 6 7 8